QTc prolongation is associated with arsenic trioxide (ATO) treatment of acute promyelocytic leukemia (APL). Olanzapine was safely co-administered with ATO to treat co-morbid psychiatric diagnoses. It is important to closely monitor for drug—drug interactions and cumulative drug adverse effects in patients receiving oncology agents and psychotropics. Further research is indicated to determine risk/benefit profiles of psychotropics co-administered with ATO. In light of current limited data, co-administration of psychotropics with ATO should be reported presenting both instances wherein no interactions are noted and those with adverse effects.
Pay VB and Napata MCCardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention . Drug Saf2000; 22(4): 263-302.
2.
Jones RL and Ewer MSCardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther2006; 6(9): 1249-1269.
3.
Douer D. and Tallman MSArsenic trioxide: new clinical experiences with an old medication in hematologic malignancies. J Clin Oncol2005; 23(10): 2396-2410.
4.
Naito K., Kobayashi M., Sahara N., Shigeno K., Nakamura S., Shinjo K., et al. Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy. Int J Hematol2006; 83(4): 318-323.
5.
Westervelt P. , Brown RA, Adkins DR, Khoury H., Curtin P., Hurd D., et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood2001; 98(2): 266-271.
6.
Arsenic Trioxide.Micromedex Healthcare Series "http://www.thomsonhc.com/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/FF044/DUPLICATIONSHIELDSYNC/FABDAF/ND_PG/PRIH/ND_B/HCS/SBK/3/ND_P/Main/PFActionId/hcs.common.RetrieveDocument/DoId/2036/ContentSetId/31" "‘precautionsSection’"http://www.thomsonhc.com/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/FF044/DUPLICATIONSHIELDSYNC/FABDAF/ND_PG/PRIH/ND_B/HCS/SBK/3/ND_P/Main/PFActionId/hcs.common.RetrieveDocument/DoId/2036/ContentSetId/31#precautionsSection (accessed 4 March 2007 and re-accessed on 4 November 2009).
7.
Goodwin JS, Zhang DD and Ostir GVEffect of depression on diagnosis, treatment, and survival of older women with breast cancer. J Am Geriatr Soc2004; 52(1): 106-111.
8.
Prieto JM, Atala J., Blanch J., Carreras E., Rovira M., Cirera E., et al. Role of depression as a predictor of mortality among cancer patients after stem-cell transplantation. J Clin Oncol2005; 23(25): 6063-6071.
9.
Pasquini M., Biondi M.Depression in cancer patients: a critical review. Clin Pract Epidemiol Ment Health2007; 3: 2 (published online 8 February 2007, doi:10.1186/1745-0179-3-2).
10.
Harter M., Reuter K., Schretzmann B., Hasenburg A., Aschenbrenner A. and Weis J.Comorbid psychiatric disorders in cancer patients in acute inpatient treatment and medical rehabilitation. Rehabilitation ( Stuttg) 2000; 39(6): 317-323.
11.
Bruera E. and Neumann CMThe uses of psychotropics in symptom management in advanced cancer. Psychooncology1998; 7(4): 346-358.
12.
Joshi N. and Breibart WSPsychopharmacologic management during cancer treatment. Semin Clin Neuropsychiatry2003; 8(4): 241-252.
13.
Pasquini M. , Biondi M., Constantini A., Cairoli F., Ferrarese G., Picardi A., et al. Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. Depress Anxiety2006; 23(7): 441-448.
14.
Strain JJ, Caliendo G. and Himelein C.Using computer databases to predict and avoid drug-drug interactions in the cancer patient requiring psychotropics. Psychooncology1998; 7(4): 321-332.
15.
American Psychiatric Association.Diagnostic and statistical manual of mental disorders, fourth ed. Washington, DC: American Psychiatric Association, 1994.
16.
Tallman MSTreatment of relapsed or refractory acute promyelocytic leukemia: best practice & research. Clin Haematol2007; 20(1): 57-65.
17.
Bonati A., Rizzoli V. and Lunghi P.Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol2006; 7(6): 397-405.
18.
Aribi A., Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia . Cancer2007; 109(7): 1355-1359.
19.
Ghavamzadeh A. , Alimoghaddam K., Ghaffari SH, Rostami S., Jahani M., Hosseini R., et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/ or chemotherapy. Ann Oncol2006; 17(1): 131-134.
20.
Zhou GB, Zhang J., Wang ZY, Chen SJ and Chen Z.Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc London. Series B, Biol Sci2007; 362(1482): 959-971.
21.
Pham CP, de Feiter PW, van der Kuy PH and van Mook WNLong QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother2006; 40(7-8): 1456-1461.
22.
Isbister GK , Bowe SJ, Dawson A. and Whyte IMRelative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol2004; 42(3): 277-285.
23.
Jeppesen U. , Gram LF, Vistisen K., Loft S., Poulsen HE and Brosen K.Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine, and paroxetine. Eur J Clin Pharmacol1996; 51(1): 73-78.
24.
Fleishaker JC and Hulst LKA pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol1994; 46(1): 35-39.
25.
Jeppesen U. , Loft S., Poulsen HE and Brsen K.A fluvoxamine-caffeine interaction study. Pharmacogenetics1996; 6(3): 213-222.
26.
Piccirillo G., Magri D., Matera S., Magnanti M., Torrini A., Pasquazzi E., et al. QT variability strongly predicts sudden cardiac death in asymptomatic subjects with mild or moderate left ventricular systolic dysfunction: a prospective study. Eur Heart J2007; 28(11): 1344-1350.
27.
Bonnet M., Tancer M., Uhde T. and Yeragani V.Effects of caffeine on heart rate and QT variability during sleep. Depress Anxiety2005; 22(3): 150-155.
Benazzi F.SSRI discontinuation syndrome related to fluvoxamine. J Psychiatry Neurosci1998; 23(2): 94.
30.
Marazziti D. , Pfanner C., Dell’Osso B., Ciapparelli A., Presta S., Corretti G., et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J Psychopharmacol2005; 19(4): 392-394.
31.
Sepede G., De Berardis D., Gambi F., Campanella D., La Rovere R., D’Amico M., et al. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol2006; 26(1): 45-49.
32.
Janenawasin S., Wang PW, Lembke A., Schumacher M., Das B., Santosa CM, et al. Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders. Bipolar Disord2002; 4(5): 328-334.
33.
Tohen M., Greil W., Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial . Am J Psychiatry2005; 162(7): 1281-1290.
34.
Harrigan EP , Miceli JJ, Anziano R., Watsky E., Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol2004; 24(1): 62-69.
35.
Dineen S., Withrow K., Voronovitch L., Munshi F., Nawbary MW and Lippmann S.QTc prolongation and high-dose olanzapine. Psychosomatics2003; 44(2): 174-175.
36.
Au WY and Kwong YLArsenic trioxide: safety issues and their management. Acta Pharmacol Sin2008; 29(3): 296-304.
37.
Mathews V., Desire S., George B., Lakshmi KM, Rao JG, Viswabandya A., et al. Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity . Leukemia2006; 20(5): 881-883.
38.
Koch JJ, Porter CJ and Ackerman MJAcquired QT prolongation associated with esophagitis and acute weight loss: how to evaluate a prolonged QT interval. Pediatr Cardiol2005; 26: 646-650.
39.
Gupta A., Lawrence AT, Krishnan K., Kavinsky CJ and Trohman RGCurrent concepts in the mechanism and management of drug-induced QT prolongation and torsade de pointes. Am Heart J2007; 153: 891-899.
40.
Abramson DW, Quinn DK and Stern TAMethadone-associated QTc prolongation: a case report and review of the literature. Prim Care Companion J Clin Psychiatry2008; 10(6): 470-476.
41.
Arsenic Trioxide.Micromedex Healthcare Series "http://www.thomsonhc.com/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/FF044/DUPLICATIONSHIELDSYNC/FABDAF/ND_PG/PRIH/ND_B/HCS/SBK/2/ND_P/Main/PFActionId/hcs.common.RetrieveDocument/DoId/2036/ContentSetId/31" "drugInteractionsSection "http://www.thomsonhc.com/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/FF044/DUPLICATIONSHIELDSYNC/FABDAF/ND_PG/PRIH/ND_B/HCS/SBK/2/ND_P/Main/PFActionId/hcs.common.RetrieveDocument/DoId/2036/ContentSetId/31#drugInteractionsSection (accessed 25 September 2009 and re-accessed on 4 November 2009).
42.
Drugs with a Risk of Torsades de Pointes, Drugs with a Possible Risk of Torsades de Pointes, and Drugs with a Conditional Risk of Torsades de Pointes. Arizona Center for Education and Research in Therapeutics. Available at: http://www.azcert.org/medical-pros/drug-lists/bycategory.cfm (accessed 28 September 2009).
